BR0014491A - Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão - Google Patents

Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão

Info

Publication number
BR0014491A
BR0014491A BR0014491-6A BR0014491A BR0014491A BR 0014491 A BR0014491 A BR 0014491A BR 0014491 A BR0014491 A BR 0014491A BR 0014491 A BR0014491 A BR 0014491A
Authority
BR
Brazil
Prior art keywords
tumor
attenuated
bacteria
attenuated bacteria
effector molecules
Prior art date
Application number
BR0014491-6A
Other languages
English (en)
Inventor
David G Bermudes
Ivan C King
Caroline A Clairmont
Stanley L Lin
Michael Belcourt
Original Assignee
Vion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc filed Critical Vion Pharmaceuticals Inc
Publication of BR0014491A publication Critical patent/BR0014491A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"BACTéRIAS ATENUADAS MARCADAS PARA TUMOR, COMPOSIçãO FARMACêUTICA, USO DE BACTéRIAS ATENUADAS, E, PROTEìNA DE FUSãO". O presente pedido divulga a preparação e o uso de vetores bacterianos atenuados marcados para tumor para a liberação de uma ou mais moléculas efetoras primárias ao sítio de um tumor sólido. A(s) molécula(s) efetora(s) primária(s) da invenção é(são) usada(s) nos métodos da invenção para tratar um câncer de tumor sólido tal como um carcinoma, melanoma, linfoma ou sarcoma. A invenção diz respeito à surpreendente descoberta de que moléculas efetoras, que podem ser tóxicas quando sistemicamente administradas a um hospedeiro, podem ser localmente liberadas a tumores por bactérias atenuadas marcadas para tumor com toxicidade reduzida ao hospedeiro. O pedido também divulga a liberação de uma ou mais moléculas efetoras opcionais (denominadas moléculas efetoras secundárias) que podem ser liberadas pelas bactérias atenuadas marcadas para tumor em conjunção com a(s) molécula(s) efetora(s) primária(s).
BR0014491-6A 1999-10-04 2000-08-24 Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão BR0014491A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15758199P 1999-10-04 1999-10-04
US15750099P 1999-10-04 1999-10-04
US15763799P 1999-10-04 1999-10-04
PCT/US2000/023242 WO2001025397A2 (en) 1999-10-04 2000-08-24 Compositions and methods for tumor-targeted delivery of effector molecules

Publications (1)

Publication Number Publication Date
BR0014491A true BR0014491A (pt) 2004-03-09

Family

ID=27388022

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014491-6A BR0014491A (pt) 1999-10-04 2000-08-24 Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão

Country Status (11)

Country Link
EP (1) EP1261369A4 (pt)
JP (1) JP2004500042A (pt)
KR (1) KR20020059605A (pt)
CN (1) CN1420783A (pt)
AU (1) AU783714B2 (pt)
BR (1) BR0014491A (pt)
CA (1) CA2386465A1 (pt)
IL (1) IL148933A0 (pt)
MX (1) MXPA02003384A (pt)
NZ (1) NZ518354A (pt)
WO (1) WO2001025397A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013053A1 (en) 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
CA2869088A1 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatments
CA2802143C (en) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Sparc encoding polynucleotide as a cancer therapy sensitizer
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
WO2005012363A1 (ja) * 2003-08-01 2005-02-10 Mochida Pharmaceutical Co., Ltd. 標的化された炎症惹起剤
CN100435850C (zh) * 2004-03-22 2008-11-26 中国医学科学院血液学研究所 具有放射保护和抗肿瘤作用的减毒沙门氏菌药物组合物
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
CN101010002B (zh) * 2004-06-29 2012-10-10 抗癌公司 癌症选择性营养缺陷型
ITRM20050422A1 (it) * 2005-08-05 2007-02-06 Consiglio Nazionale Ricerche Fattori proteici dermonecrotizzanti di origine batterica e relativi usi in campo medico.
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8357486B2 (en) 2008-01-11 2013-01-22 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
CN102604949A (zh) * 2011-04-12 2012-07-25 南京大学 一种乙醇脱氢酶启动子驱动的厌氧组织选择性基因表达方法及应用
WO2013128288A1 (en) * 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
CN102731658B (zh) * 2012-05-15 2014-07-30 山东大学 一种Tat PTD-Endostatin重组蛋白及其制备方法与应用
JP6125041B2 (ja) * 2013-01-02 2017-05-10 デコイ バイオシステムズ インコーポレイテッドＤｅｃｏｙ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． 細菌を用いた癌治療用組成物およびその製造のための菌の使用
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2829274A1 (en) 2013-07-25 2015-01-28 Institut National De La Recherche Agronomique Vectors for producing and secreting substance of interest by bacteria and applications thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR101685034B1 (ko) * 2015-04-10 2016-12-09 전남대학교 산학협력단 고형암 조직 타겟팅 박테리아 및 그의 용도
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN107537027A (zh) * 2016-06-23 2018-01-05 南开大学 Tnfsf15蛋白在制备治疗黑色素瘤药物中的用途
EP3565566A1 (en) * 2017-01-06 2019-11-13 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
CN107115533A (zh) * 2017-04-01 2017-09-01 广州华津医药科技有限公司 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用
KR20200064980A (ko) * 2017-07-12 2020-06-08 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물
AU2017430856A1 (en) 2017-09-08 2020-04-02 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN110423772B (zh) * 2019-07-17 2023-04-21 上海科技大学 一种用于鲍曼不动杆菌胞嘧啶碱基编辑质粒及其应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114438111B (zh) * 2020-11-05 2023-08-11 深圳先进技术研究院 Pp2严格厌氧沙门氏菌菌株构建及其在肿瘤治疗方面应用
WO2023041809A1 (en) * 2021-09-20 2023-03-23 Pulmobiotics, S.L. Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms
CN116676324B (zh) * 2023-07-28 2023-10-27 四川大学华西医院 基于Kil蛋白构建释放抗肿瘤效应蛋白的系统及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338679A3 (en) * 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
CA2231332C (en) * 1995-09-06 2007-04-17 Arthur A. Branstrom Bacterial delivery system
WO1999013053A1 (en) * 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Also Published As

Publication number Publication date
EP1261369A4 (en) 2006-02-01
AU783714B2 (en) 2005-12-01
KR20020059605A (ko) 2002-07-13
CA2386465A1 (en) 2001-04-12
IL148933A0 (en) 2002-09-12
WO2001025397A2 (en) 2001-04-12
MXPA02003384A (es) 2002-08-20
NZ518354A (en) 2005-02-25
JP2004500042A (ja) 2004-01-08
CN1420783A (zh) 2003-05-28
AU6933400A (en) 2001-05-10
EP1261369A2 (en) 2002-12-04
WO2001025397A3 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
BR0014491A (pt) Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
BRPI9809468B8 (pt) Formulações farmacêuticas contendo voriconazol
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BR0210028A (pt) Agentes antibacterianos
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AU2002359122A1 (en) Novel compounds
BRPI0510628A (pt) polìmeros à base de celulose e acrìlicos, e uso dos mesmos para o tratamento de doenças infecciosas
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0312845A (pt) Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
BR0113590A (pt) 7-oxo-piridopirimidinas
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
NO990833D0 (no) Farmas°ytiske forbindelser
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]